Allena Pharmaceuticals

Super Nova Resources, Inc. engages in the provision of video communication services. It provides GreenLink Video Assistance and Point-of-Decision Systems through its subsidiary. It offers live, real-time, and bi-directional personal video communication between customers and customer service representatives stationed in centralized video command centers. The company was founded in 1965 and is headquartered in Corona, CA.

NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena's President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020, at 1:25 p.m. ET.  

Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

-- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperoxaluria (EH) -- -- Completed Dosing of Subjects in Ph ase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 –

Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:

Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Allena Pharmaceuticals, Inc. (ALNA) a New Buy Stock

NEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Ann Miller, M.D., to its board of directors.

Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors

-- Extends Allena’s Cash Runway into 4Q 2021 -- -- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into a $25 million convertible debt financing agreement with Pontifax Medison Finance, the healthcare-dedicated venture and debt fund of the Pontifax life science funds.

Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

NEWTON, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September:

Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September

-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –-

Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

NEWTON, Mass., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020, at 8:35 a.m. ET.  

Allena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

NEWTON, Mass., July  27, 2020  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 5,125,384 shares of common stock of the Company, at a price to the public of $1.30 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 30, 2020, subject to satisfaction of customary closing conditions.

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million

NEWTON, Mass., July  27, 2020  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 3,846,154 shares of common stock of the Company, at a price to the public of $1.30 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 30, 2020, subject to satisfaction of customary closing conditions.

Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering

NEWTON, Mass., June  03, 2020  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,317,074 shares of the Company’s common stock, at a purchase price of $2.05 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 5, 2020, subject to the satisfaction of customary closing conditions.

Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial --    -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 --

Allena Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Allena Pharmaceuticals, Inc. (ALNA) Moves to Strong Buy: Rationale Behind the Upgrade

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why

– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) –

Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

Allena Pharmaceuticals: Rating This Stock A Buy

Allena Demolished: Weak Phase III And Dismal Prognosis

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria

Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206

Topline data from URIROX-1 expected in 4Q 2019 Topline data from URIROX-1 expected in 4Q 2019

Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

NEWTON, Mass., Sept.  11, 2019  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader symposium on the unmet need in enteric hyperoxaluria and the potential for reloxaliase as a first-in-class therapy for patients. The event will be held on Wednesday, September 18, 2019 from 8:30 a.m. to 10:00 a.m. ET in New York.

Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase

Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type of kidney stone.

Allena Pharmaceuticals: Unique Treatment For Enteric Hyperoxaluria Not Reflected In Valuation

NEWTON, Mass., Aug.  29, 2019  (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three investor conferences in September:

News for Allena Pharmaceuticals Stock (ALNA)